Search

Your search keyword '"Kukreti, Vishal"' showing total 48 results
Start Over Author "Kukreti, Vishal" Publication Year Range Last 3 years
48 results on '"Kukreti, Vishal"'

6. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP

Author

Stewart, Douglas A., primary, Kuruvilla, John, additional, Lee, David, additional, Dudebout, Jill J., additional, Chua, Neil, additional, Larouche, Jean‐François, additional, Baetz, Tara, additional, Shafey, Mona, additional, Abdel‐Samad, Nizar, additional, Robinson, Sue, additional, Fleury, Isabelle, additional, Fraser, Graeme, additional, Skrabek, Pamela, additional, Kukreti, Vishal, additional, Kelly, Jesse, additional, Hay, Annette E., additional, Shepherd, Lois E., additional, Chen, Bingshu E., additional, and Crump, Michael, additional

Published
2024
Full Text
View/download PDF

14. The I-Can Manage web-based cancer self-management program targeting treatment toxicities and health behaviours: Human centred co-design approach and cognitive-think aloud usability testing (Preprint)

Author

Howell, Doris, primary, Bryant Lukosius, Denise, additional, Avery, Jonathan, additional, Santaguida, Athina, additional, Powis, Melanie, additional, Papadakos, Tina, additional, Addario, Vincenzo, additional, Lovas, Mike, additional, Kukreti, Vishal, additional, Haase, Kristen, additional, Mayo, Samantha, additional, Papadakos, Janet, additional, Moradian, Saeed, additional, and Krzyzanowska, Monica, additional

Published
2022
Full Text
View/download PDF

15. Human centered co-design and usability testing of a web-based cancer self-management education program (I-Can Manage) targeting treatment toxicities and health behaviours (Preprint)

Author

Howell, Doris, primary, Bryant Lukosius, Denise, additional, Avery, Jonathan, additional, Santaguida, Athina, additional, Powis, Melanie, additional, Papadakos, Tina, additional, Addario, Vincenzo, additional, Lovas, Mike, additional, Kukreti, Vishal, additional, Haase, Kristen, additional, Mayo, Samantha, additional, Papadakos, Janet, additional, Moradian, Saeed, additional, and Krzyzanowska, Monica, additional

Published
2022
Full Text
View/download PDF

16. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

Author

Patel, Ashish, primary, Smith, Adam C., additional, Masih-Khan, Esther, additional, Samuel, Peace, additional, Lajkosz, Katherine, additional, Bhella, Sita, additional, Chen, Christine I., additional, Prica, Anca, additional, Reece, Donna E., additional, Stewart, A. Keith, additional, Tiedemann, Rodger E, additional, Trudel, Suzanne, additional, Yang, Chloe, additional, and Kukreti, Vishal, additional

Published
2022
Full Text
View/download PDF

18. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Author

Prica, Anca, primary, Coley, Tiana, additional, Aitken, Rachel, additional, Vijenthira, Abi, additional, Maganti, Manjula, additional, Mayo, Samantha J, additional, Chen, Christine I., additional, Kuruvilla, John, additional, Crump, Michael, additional, Bhella, Sita, additional, Kridel, Robert, additional, Kukreti, Vishal, additional, Yang, Chloe, additional, and Alibhai, Shabbir, additional

Published
2022
Full Text
View/download PDF

19. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Author

Devasia, Anup Joseph, primary, Khan, Sahar, additional, Paul, Harminder K, additional, Larose, Frédéric, additional, Atenafu, Eshetu G., additional, Reece, Donna E., additional, Trudel, Suzanne, additional, Stewart, A. Keith, additional, Bhella, Sita, additional, Kukreti, Vishal, additional, Yang, Chloe, additional, Tiedemann, Rodger E, additional, Prica, Anca, additional, Monchis, Monica, additional, Leung, Eugene, additional, Jomah, Susan, additional, Mohamed, Zubaida, additional, and Chen, Christine, additional

Published
2022
Full Text
View/download PDF

20. Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Author

Hershenfeld, Samantha A, primary, Shelton, Victoria, additional, Bakhtiari, Mehran, additional, Calvente, Lourdes, additional, Lajkosz, Katherine, additional, Isaev, Keren, additional, Silva, Anjali, additional, Liu, Ting, additional, Brodtkorb, Marianne, additional, d'Amore, Francesco Annibale, additional, Ludvigsen, Maja, additional, Madsen, Charlotte, additional, Hamilton-Dutoit, Stephen, additional, Gandhi, Maher, additional, Tobin, Joshua W.D., additional, Baetz, Tara, additional, LeBrun, David, additional, Johnson, Nathalie A., additional, Mungall, Andrew J., additional, Crump, Michael, additional, Delabie, Jan, additional, Gospodarowicz, Mary, additional, Hodgson, David, additional, Hong, Michael, additional, Kukreti, Vishal, additional, Kuruvilla, John, additional, Prica, Anca, additional, Tremblay-Lemay, Rosemarie, additional, Tsang, Richard, additional, and Kridel, Robert, additional

Published
2022
Full Text
View/download PDF

21. From Choosing Wisely to Implementing Wisely in Cancer Care: A Scoping Review

Author

Kukreti, Vishal, Milley-Daigle, Carissa, Powis, Melanie, and Krzyzanowska, Monika

Subjects
Oncology, quality, Neoplasms, Medicine and Health Sciences, Medical Specialties, choosing wisely, Diseases, cancer care
Abstract

We will be conducting a scoping review to determine the extent of the implementation of the Choosing Wisely campaign in cancer care.

Published
2022
Full Text
View/download PDF

23. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

Author

Lackraj, Tracy, primary, Ben Barouch, Sharon, additional, Medeiros, Jessie J. F., additional, Pedersen, Stephanie, additional, Danesh, Arnavaz, additional, Bakhtiari, Mehran, additional, Hong, Michael, additional, Tong, Kit, additional, Joynt, Jesse, additional, Arruda, Andrea, additional, Minden, Mark D., additional, Kuruvilla, John, additional, Bhella, Sita, additional, Kukreti, Vishal, additional, Crump, Michael, additional, Prica, Anca, additional, Chen, Christine, additional, Deng, Yangqing, additional, Xu, Wei, additional, Pugh, Trevor J., additional, Keating, Armand, additional, Dick, John E., additional, Abelson, Sagi, additional, and Kridel, Robert, additional

Published
2022
Full Text
View/download PDF

26. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

Author

Yhim, Ho‐Young, primary, Eshet, Yael, additional, Metser, Ur, additional, Lajkosz, Katherine, additional, Cooper, Matthew, additional, Prica, Anca, additional, Kukreti, Vishal, additional, Bhella, Sita, additional, Lang, Noémie, additional, Xu, Wei, additional, Rodin, Danielle, additional, Hodgson, David, additional, Tsang, Richard, additional, Crump, Michael, additional, Kuruvilla, John, additional, and Kridel, Robert, additional

Published
2022
Full Text
View/download PDF

28. Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience

Author

Manji, Farheen, primary, Chow, Eric, additional, Gerrie, Alina S., additional, Chua, Neil, additional, Puckrin, Robert, additional, Stewart, Douglas A., additional, Skrabek, Pamela, additional, Bence-Bruckler, Isabelle, additional, Keating, Mary-Margaret, additional, Britto, Joanne, additional, Davies, Gwynivere A, additional, Kukreti, Vishal, additional, Kuruvilla, John, additional, and Crump, Michael, additional

Published
2021
Full Text
View/download PDF

29. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Author

Yhim, Ho-Young, primary, Eshet, Yael, additional, Metser, Ur, additional, Lajkosz, Katherine, additional, Cooper, Matthew, additional, Prica, Anca, additional, Kukreti, Vishal, additional, Bhella, Sita, additional, Lang, Noemie, additional, Xu, Wei, additional, Rodin, Danielle, additional, Hodgson, David, additional, Tsang, Richard, additional, Crump, Michael, additional, Kuruvilla, John, additional, and Kridel, Robert, additional

Published
2021
Full Text
View/download PDF

31. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

Author

Ben Barouch, Sharon, primary, Lackraj, Tracy, additional, Medeiros, Jessie, additional, Bakhtiari, Mehran, additional, Joynt, Jesse, additional, Tong, Kit, additional, Arruda, Andrea, additional, Minden, Mark D., additional, Alvarez, Mileidys, additional, Kuruvilla, John, additional, Bhella, Sita, additional, Kukreti, Vishal, additional, Crump, Michael, additional, Prica, Anca, additional, Chen, Christine I., additional, Keating, Armand, additional, Dick, John E., additional, Abelson, Sagi, additional, and Kridel, Robert, additional

Published
2021
Full Text
View/download PDF

33. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Author

Prica, Anca, primary, Dhir, Vinita, additional, Aitken, Rachel, additional, Paul, Harminder K, additional, Espin-Garcia, Osvaldo, additional, Bhella, Sita, additional, Chen, Christine I., additional, Crump, Michael, additional, Kridel, Robert, additional, Kukreti, Vishal, additional, Kuruvilla, John, additional, Reece, Donna E., additional, Tiedemann, Rodger E, additional, and Trudel, Suzanne, additional

Published
2021
Full Text
View/download PDF

36. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis

Author

Rivera Duarte, Alfonso, primary, Reece, Donna, additional, Li, Xuan, additional, Xu, Wei, additional, Paul, Harminder, additional, Masih-Khan, Esther, additional, Winter, Andrew, additional, Tiedemann, Rodger, additional, Prica, Anca, additional, Chen, Christine, additional, Trudel, Suzanne, additional, and Kukreti, Vishal, additional

Published
2021
Full Text
View/download PDF

37. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.

Author

Rivera Duarte, Alfonso, Reece, Donna, Li, Xuan, Xu, Wei, Paul, Harminder, Masih-Khan, Esther, Winter, Andrew, Tiedemann, Rodger, Prica, Anca, Chen, Christine, Trudel, Suzanne, and Kukreti, Vishal

Subjects
AMYLOIDOSIS, TREATMENT duration, PROGRESSION-free survival, MULTIPLE myeloma
Abstract

The main objective of treatment in systemic light chain amyloidosis (AL amyloidosis) is to achieve the best hematological response. Deeper responses are associated with better organ responses and survival. In this study, we analysed the efficacy of prolonged duration treatment after first line in patients with AL amyloidosis. Retrospective analysis that included patients older than 18 years with AL amyloidosis. We excluded patients with more than 30% marrow plasmacytosis or concurrent multiple myeloma. Two cohorts identified accordingly if they received or not prolonged treatment after the first line. Survival analysis regarding progression free survival (PFS) and overall survival (OS) estimated with Kaplan–Meier and comparisons between groups with log-rank. Thirty-eight patients were included in the analysis with a median age of 55 years. Twenty-one patients received prolonged duration treatment and 17 did not. In the prolonged duration group, after a median duration of 12 months, the median PFS was 58.8 months. In the fixed duration treatment group, PFS was 30.6 months. The difference was significant with p =.0045 favouring prolonged duration treatment. Organ response was sustained for a longer period in the prolonged duration treatment group. For OS, the difference was not significant. Prolonged duration treatment in patients with systemic light chain amyloidosis correlated with better PFS and deeper organ responses. Prospective studies are needed to analyse this further. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.

Author

Lebel, Eyal, Li, Xuan, Paul, Harminder, Masih‐Khan, Esther, Bhella, Sita, Chen, Christine, Prica, Anca, Reece, Donna, Tiedemann, Rodger, Trudel, Suzanne, and Kukreti, Vishal

Subjects
MULTIPLE myeloma, AUTOGRAFTS, PROGNOSIS, LENALIDOMIDE, MELPHALAN
Abstract

Objectives: The prognostic value of kinetics of response to multiple myeloma (MM) therapy is controversial. We aimed to expand the knowledge on this topic by reviewing the kinetics of response to both first‐ and second‐line MM therapy, utilizing a homogeneously treated cohort and analyzing separately both M‐spike and light chain (LC) responses for each patient. Methods: We reviewed all patients who received first‐line cyclophosphamide, bortezomib and dexamethasone induction followed by autologous transplant with melphalan and lenalidomide maintenance in our center between 2007 and 2019. Results: Analyzing 360 patients, we observed no correlation between response kinetics to first‐ versus second‐line therapy at the individual patient level. Time to best response to first‐line therapy was not a predictor of outcome; however, longer time to best response was highly predictive of a favorable outcome in the second‐line setting, independent of other factors. Patients with IgA‐MM cleared their M‐spike faster than IgG‐MM, probably reflecting different half‐lives of these isotypes rather than disease biology, as the clearance of LC in both subtypes was similar. Conclusions: Analyzing both M‐spike and LC responses in a homogenously treated cohort, we identified important insights regarding the prognostic value of kinetic patterns. Prospective analysis may shed more light on unsolved questions. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

Author

Monteith, Bethany E., Venner, Christopher P., Cheung, Matthew C., Pater, Joe, Shepherd, Lois, Richardson, Harriet, Reece, Donna, Gul, Engin, Lalancette, Marc, Castonguay, Vincent, Kukreti, Vishal, Tiedemann, Rodger, Phua, Chai, Bhella, Sita, Dudebout, Jill, Sherry, Max, Yen, Hope, Chen, Bingshu E., and Hay, Annette E.

Subjects
MULTIPLE myeloma, CYCLOPHOSPHAMIDE, PLASMA exchange (Therapeutics), COST analysis, CLINICAL trials
Abstract

Background: The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020). The MYX.1 phase II trial showed that high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wKCD) is efficacious in relapsed and refractory disease. We conducted a descriptive cost analysis, from the perspective of the Canadian public healthcare system, using trial data. Methods: The primary outcome was the mean total cost per patient. Resource utilization data were collected from all 75 trial patients over a trial time horizon. Costs are presented in Canadian dollars (2020). Results: The cost of treatment was calculated from the time of patient (pt) enrollment until the second data lock. The mean total cost was $203 336.08/pt (range $17 891.27‐$505 583.55) Canadian dollars (CAD, where 1 CAD = 0.67 Euro (EUR)) and $14 081.45/pt per cycle. The median number of cycles was 15. The predominant cost driver was the cost of chemotherapy accounting for an average of $179 332.78/pt or $12 419.17/pt per cycle. Carfilzomib acquisition accounted for the majority of chemotherapy costs – $162 471.65/pt or $11 251.50/pt per cycle. Fifty‐six percent (56%) of patients had at least one hospitalization during the trial period with an average cost of $12 657.86 per hospitalization. Three patients developed thrombotic microangiopathy (TMA) with an average cost of $18 863.32/pt including the cost of hospitalizations and therapeutic plasma exchange. Conclusions: High‐dose wKCD is an active triplet regimen for relapsed and refractory multiple myeloma (RRMM) associated with reduced total cost compared with twice‐weekly carfilzomib‐based regimens. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

41. Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Author

Devasia, Anup J, Khan, Sahar, Atenafu, Eshetu, Vohra, Harjot, Larose, Frédéric, Reece, Donna, Trudel, Suzanne, Stewart, A. Keith, Bhella, Sita D., Kukreti, Vishal, Yang, Chloe, Tiedemann, Rodger E., Prica, Anca, Monchis, Monica, Leung, Eugene, Zeglinski, Christina, Mohamed, Zubaida, and Chen, Christine

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

44. Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

Author

Hodgson, David, Aminilari, Mahmood, Liao, Donna, Ye, Xiang Y, Metser, Ur, Crump, Michael, Kuruvilla, John, Vijenthira, Abi, Kukreti, Vishal, Kridel, Robert, Tsang, Richard, Bhella, Sita D., Rodin, Danielle, and Prica, Anca

Abstract

Background:The optimal management of patients with primary mediastinal B-cell lymphoma (PMBCL) who experience a partial metabolic response (PMR) on FDG-PET after initial systemic therapy is unclear. This study aimed to investigate different management strategies and outcomes for PMBCL patients who achieved PMR following primary systemic therapy, utilizing a single-center retrospective design.

Published
2023
Full Text
View/download PDF

45. Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Author

Khan, Sahar, Basrai, Salman, Reece, Donna, Bhella, Sita D., Kukreti, Vishal, Prica, Anca, Stewart, A. Keith, Trudel, Suzanne, Vohra, Harjot, Yang, Chloe, Abelson, Sagi, and Chen, Christine

Abstract

Background:

Published
2023
Full Text
View/download PDF

46. CrebbpMutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Author

Hershenfeld, Samantha A, Shelton, Victoria, Bakhtiari, Mehran, Calvente, Lourdes, Lajkosz, Katherine, Isaev, Keren, Silva, Anjali, Liu, Ting, Brodtkorb, Marianne, d'Amore, Francesco Annibale, Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, Gandhi, Maher, Tobin, Joshua W.D., Baetz, Tara, LeBrun, David, Johnson, Nathalie A., Mungall, Andrew J., Crump, Michael, Delabie, Jan, Gospodarowicz, Mary, Hodgson, David, Hong, Michael, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, Tremblay-Lemay, Rosemarie, Tsang, Richard, and Kridel, Robert

Published
2022
Full Text
View/download PDF

47. Supermobilizers with High CD34 +Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Author

Lebel, Eyal, Lajkosz, Katherine, Masih-Khan, Esther, Reece, Donna E., Trudel, Suzanne, Tiedemann, Rodger E, Prica, Anca, Kukreti, Vishal, and Chen, Christine I.

Abstract

Introduction:Autologous stem cell transplantation (ASCT) is standard therapy for selected patients with newly diagnosed multiple myeloma (MM). Studies in MM and lymphoma have suggested that ability to mobilize and collect a higher yield of CD34 +cells predicts for improved survival outcomes, perhaps reflecting better bone marrow reserve (Bolwell 2007, Raschle 2011). We aimed to validate this hypothesis by correlating high CD34 +cell collection (“supermobilizers”) and survival outcomes in a large myeloma cohort with long follow-up.

Published
2021
Full Text
View/download PDF

48. A Web-Based Cancer Self-Management Program (I-Can Manage) Targeting Treatment Toxicities and Health Behaviors: Human-Centered Co-design Approach and Cognitive Think-Aloud Usability Testing.

Author

Howell D, Bryant Lukosius D, Avery J, Santaguida A, Powis M, Papadakos T, Addario V, Lovas M, Kukreti V, Haase K, Mayo SJ, Papadakos J, Moradian S, and Krzyzanowska MK

Abstract

Background: Patients with cancer require adequate preparation in self-management of treatment toxicities to reduce morbidity that can be achieved through well-designed digital technologies that are developed in co-design with patients and end users., Objective: We undertook a user-centered co-design process in partnership with patients and other knowledge end users to develop and iteratively test an evidence-based and theoretically informed web-based cancer self-management program (I-Can Manage). The specific study aims addressed in 2 phases were to (1) identify from the perspective of patients with cancer and clinicians the desired content, features, and functionalities for an online self-management education and support (SMES) program to enable patient self-management of treatment toxicities (phase 1); (2) develop the SMES prototype based on human-centered, health literate design principles and co-design processes; and (3) evaluate usability of the I-Can Manage prototype through user-centered testing (phase 2)., Methods: We developed the I-Can Manage program using multiperspective data sources and based on humanistic and co-design principles with end users engaged through 5 phases of development. We recruited adult patients with lung, colorectal, and lymphoma cancer receiving systemic treatments from ambulatory clinics in 2 regional cancer programs for the qualitative inquiry phase. The design of the program was informed by data from qualitative interviews and focus groups, persona and journey mapping, theoretical underpinnings of social cognitive learning theory, and formalized usability testing using a cognitive think-aloud process and user satisfaction survey. A co-design team comprising key stakeholders (human design experts, patients/caregiver, clinicians, knowledge end users, and e-learning and digital design experts) was involved in the developmental process. We used a cognitive think-aloud process to test usability and participants completed the Post-Study System Usability Questionnaire (PSSUQ)., Results: In the initial qualitative inquiry phase, 16 patients participated in interviews and 19 clinicians participated in interviews or focus groups and 12 key stakeholders participated in a persona journey mapping workshop to inform development of the program prototype. The I-Can Manage program integrates evidence-based information and strategies for the self-management of treatment toxicities and health-promoting behaviors in 6 e-learning modules (lay termed "chapters"), starting with an orientation to self-management. Behavioral exercises, patient written and video stories, downloadable learning resources, and online completion of goals and action plans were integrated across chapters. Patient participants (n=5) with different cancers, gender, and age worked through the program in the human factors laboratory using a cognitive think-aloud process and all key stakeholders reviewed each chapter of the program and approved revisions. Results of the PSSUQ (mean total score: 3.75) completed following the cognitive think-aloud process (n=5) suggest patient satisfaction with the usability of I-Can Manage., Conclusions: The I-Can Manage program has the potential for activating patients in self-management of cancer and treatment toxicities but requires testing in a larger randomized controlled trial., (©Doris Howell, Denise Bryant Lukosius, Jonathan Avery, Athina Santaguida, Melanie Powis, Tina Papadakos, Vincenzo Addario, Mike Lovas, Vishal Kukreti, Kristen Haase, Samantha J Mayo, Janet Papadakos, Saeed Moradian, Monika K Krzyzanowska. Originally published in JMIR Cancer (https://cancer.jmir.org), 21.07.2023.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results